Whole Genome And Exome Sequencing: A Leading Driver Behind The Surge In Demand For Personalized Medicine Boosts The Whole Genome And Exome Sequencing Market Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Will the Whole Genome And Exome Sequencing Industry Market Size Be by 2025?
The market size for entire genome and exome sequencing has been witnessing a substantial upsurge in recent years. It is projected to rise from $2.02 billion in 2024 to $2.53 billion in 2025, with an expected compound annual growth rate (CAGR) of 24.8%. The notable growth during the historic period can be credited to factors such as a decline in sequencing expenses, the increasing prevalence of genetic disorders, clinical applications, the emergence of genomic data repositories, and advancements in the field of bioinformatics.

What's the Long-Term Growth Forecast for the Whole Genome And Exome Sequencing Market Size Through 2029?
Expectations are high for an explosive expansion in the size of the whole genome and exome sequencing market over the upcoming years. It is projected to reach $6.14 billion by 2029, growing at a compound annual growth rate (CAGR) of 24.9%. The surge anticipated during the projection period is being attributed to factors such as population genomics initiatives, an increasing demand for precision medicine, developments in single-cell sequencing, an upswing in non-invasive prenatal testing (NIPT), and the application of these technologies in researching rare diseases. Key trends to watch during this forecast period include further clinical adoption, swift developments in sequencing technologies, the ascent of population-scale genomic studies, the merging of artificial intelligence (AI) and machine learning (ML), and ever-wider applications within the field of oncology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/whole-genome-and-exome-sequencing-global-market-report

What Are the Key Growth Drivers Fueling the Whole Genome And Exome Sequencing Market Expansion?
The increasing requirement for bespoke medical treatment is anticipated to drive the development of the whole genome and exome sequencing market in the coming years. Personalized medicine, which tweaks health decisions and treatments according to the unique attributes of every patient, taking into account factors like genetics, atmosphere, and lifestyle, forms the cornerstone of this growth. It leverages whole genome and exome sequencing to conduct an all-encompassing study of an individual's genetic constitution, enabling health decisions and treatments that reflect their exclusive genetic, environmental, and lifestyle factors. For example, come October 2022, the US-based Personalized Medicine Coalition (PMC), which champions the comprehension and adoption of personalized medicine, predicts more than 75,000 genetic testing products and 300 personalized medicines to be on the market in 2022. Additionally, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) greenlit 37 new molecular entities (NMEs) in 2022. Notably, roughly 34% (or 12) of the 35 therapeutic NMEs are categorized as personalized. Thus, the escalating demand for personalized medicine is spurring the expansion of the whole genome and exome sequencing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13957&type=smp

What Are the Key Trends Driving Whole Genome And Exome Sequencing Market Growth?
Leading corporations in the whole genome and exome sequencing industries are concentrating on the development of highly innovative technological solutions like ultra-fast NGS (next-generation sequencing) analysis to establish a strong market presence. Ultra-fast NGS analysis is a technological breakthrough that processes next-generation sequencing (NGS) data at an incredibly fast pace, drastically shrinking the time necessary for the analysis of genomic data. For instance, QIAGEN Digital Insights (QDI), a bioinformatics organization based in the United States, introduced the ultra-fast NGS analysis platform in January 2023. Its platform provides features such as processing an entire genome in 25 minutes at $1 in cloud computing expenses, thereby enhancing efficiency, affordability and scalability. This innovative technology greatly improves the speed and accessibility of genomic data analysis, making it especially relevant in the whole genome and exome sequencing market due to its potential to expedite decision-making and facilitate the widespread implementation of personalized medicine.

How Is the Whole Genome And Exome Sequencing Market Segmented?
The whole genome and exome sequencing market covered in this report is segmented -

1) By Product Type: Kits, Instruments
2) By Workflow: Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES)
3) By Applications: Diagnostics, Cancer, Monogenic Disorders, Diabetes, Drug Discovery And Development, Personalized Medicine, Agriculture And Animal Research, Other Applications
4) By End user: Research Center, Academic And Government Institutions, Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:
1) By Kits: Library Preparation Kits, Target Enrichment Kits, DNA Extraction Kits
2) By Instruments: Next-Generation Sequencing (NGS) Systems, Sanger Sequencing Systems, Third-Generation Sequencing Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13957&type=smp

Which Companies Are Leading the Charge in Whole Genome And Exome Sequencing Market Innovation?
Major companies operating in the whole genome and exome sequencing market report are Siemens AG, Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings (Labcorp), Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Canon Medical Systems Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V, Neusoft Corporation, BGI Genomics, Mirion Technologies (Capintec) Inc., Novogene Co., Oxford Nanopore Technologies Inc., LANDAUER, Pacific Biosciences of California Inc., Digirad Corporation, Berthold Technologies GmbH & Co.KG, GENEWIZ Inc., Incom Inc., Lucerno Dynamics LLC, Absolute Imaging Inc., Mediso Ltd., Ashby Gorman Baker Ltd., DDD-Diagnostic AS, SurgicEye GmbH, CMR Naviscan

Which Regions Are Leading the Global Whole Genome And Exome Sequencing Market in Revenue?
North America was the largest region in the whole genome and exome sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the whole genome and exome sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13957

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.